RESEARCH Metal-chloroquine derivat a o

Full list of author information is available at the end of the articlepopulation, live in at-risk regions for malaria infection. In 2013, an estimated 207 million episodes of malaria oc-curred, and approximately 627,000 people died [1]. Of the five typically recognized Plasmodium species causing this disease in humans, Plasmodium falciparum is responsible for about 95 % of malaria worldwide and has a mortality rate of 1–3%, and Plasmodium vivax for most morbidity, efforts [2,3]. When chloroquine resistant (CQR) malaria parasites started to emerge in Asia and South America and spread from Asia to Africa, and lost its efficiency as a first line anti-malarial drug, this was a major setback to the effect-ive control of malaria. Currently, malaria is treated with a combination of two or more drugs with different modes of action to provide an adequate cure rate and delay develop-ment of resistance. A strategy for the development of alternative therapies against malaria has been based on the modification o